Drug
DNR
DNR is a pharmaceutical drug with 3 clinical trials. Historical success rate of 50.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 1 completed trials
Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
100%(1 trials)
Terminated
1(33%)
Phase Distribution
Ph phase_2
1
33%
Ph phase_4
1
33%
Phase Distribution
0
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
Phase 4Post-market surveillance
1(50.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(1)
Terminated(1)
Other(1)
Detailed Status
unknown1
Completed1
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
50.0%
Most Advanced
Phase 4
Trials by Phase
Phase 21 (50.0%)
Phase 41 (50.0%)
Trials by Status
unknown133%
completed133%
terminated133%
Recent Activity
0 active trials
Showing 3 of 3
terminatedphase_2
Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma
NCT02043587
completedphase_4
Cytarabine (Ara-C) in Children With Acute Promyelocytic Leukemia (APL)
NCT01191541
unknown
Comparison of Liposomal Doxorubicin and Daunorubicin-containing VDCLD Regimen in the Treatment of Adult ALL Patients
NCT03419494
Clinical Trials (3)
Showing 3 of 3 trials
NCT02043587Phase 2
Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma
NCT01191541Phase 4
Cytarabine (Ara-C) in Children With Acute Promyelocytic Leukemia (APL)
NCT03419494
Comparison of Liposomal Doxorubicin and Daunorubicin-containing VDCLD Regimen in the Treatment of Adult ALL Patients
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3